ClinConnect ClinConnect Logo
Search / Trial NCT03681340

Remineralization Effects of Hydroxyapatite Toothpaste

Launched by DR. JOACHIM ENAX · Sep 21, 2018

Trial Information

Current as of August 02, 2025

Completed

Keywords

ClinConnect Summary

The investigators hypothesize that (1) both the hydroxyapatite and the fluoridated toothpaste promote caries remineralization that is significantly greater than zero, and (2) the two toothpaste formulations are equally effective with respect to post-treatment remineralization and inhibition of demineralization.

* Non-inferiority will be considered established if there is no statistically significant difference in percentage of remineralization between the hydroxyapatite-containing toothpaste and the fluoridated kid's toothpaste for any one measurement method.
* Superiority/inferiority will...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male and/or female subjects 18 to 50 years inclusive
  • 2. Minimum of 20 natural uncrowned teeth (excluding third molars) must be present
  • 3. Willing to wear retainer 24 hours per day
  • 4. No active, unrestored cavities
  • 5. Have normal salivary flow rate (stimulated and unstimulated flow of ≥0.7 ml/min and ≥0.2 ml/min respectively) ascertained from a preliminary sialometry test
  • 6. Available throughout entire study
  • 7. Willing to use only assigned products for oral hygiene throughout the duration of the study
  • 8. Must give written informed consent
  • 9. Must be in good general health
  • 10. No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study
  • Exclusion Criteria:
  • 1. Advanced periodontal disease
  • 2. Medical condition which requires premedication prior to dental visits/procedures
  • 3. Not enough teeth to secure the oral retainer
  • 4. Diseases of the soft or hard oral tissues
  • 5. Wearing of an orthodontic retainer(s)
  • 6. Impaired salivary function
  • 7. Current use of drugs that can affect salivary flow
  • 8. Use of antibiotics one (1) month prior to or during this study
  • 9. Positive urine test for pregnancy or self-reported breastfeeding. A urine pregnancy test will be performed on female subjects of child-bearing potential.
  • 10. Participation in another clinical study one (1) week prior to the start of the washout period or during this study period
  • 11. Use of tobacco products
  • 12. Allergic history to common toothpaste ingredients
  • 13. Allergic history to amino acids
  • 14. Immune compromised individuals (HIV, AIDS, immuno-suppressive drug therapy) as determined by review of medical history

About Dr. Joachim Enax

Dr. Joachim Enax is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical trial design and execution, Dr. Enax leads innovative studies that focus on evaluating new therapeutic interventions across various medical fields. His dedication to scientific rigor and ethical standards ensures that all trials are conducted in compliance with regulatory requirements, fostering a collaborative environment for researchers and healthcare professionals. Through his leadership, Dr. Enax aims to contribute meaningful insights to the medical community and enhance the development of effective treatment options.

Locations

San Antonio, Texas, United States

San Antonio, Texas, United States

Patients applied

0 patients applied

Trial Officials

Bennett T. Amaechi, Prof.

Principal Investigator

The University of Texas Health Science Center at San Antonio

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials